Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Drug Development For Metabolic Syndrome Is Stunted By Inadequate Definitions

This article was originally published in The Pink Sheet Daily

Executive Summary

Pfizer's Fryburg says treatment of the syndrome may not offer benefit over treatment of individual disease components.

You may also be interested in...

Pfizer Focusing Obesity Rx Development Efforts On Combination Therapies

The company's antihypertensive/cholesterol-lowering agent Caduet and the atorvastatin/torcetrapib combination have potential for use in metabolic syndrome, Pfizer VP-Cardiovascular Medical Group Palmer says. Future obesity therapies will require comparable efficacy to Abbott's Meridia but with a more tolerable safety profile, he says.

NEJM, JAMA Editorials Give Opposing Opinions Of Mandatory HPV Vaccination

Two of the leading medical journals are offering opposing viewpoints on mandatory human papilloma virus vaccination, with experts contributing perspective pieces that directly reflect the larger political and social division over the issue

FDA’s Arcoxia Decision Offers New Evidence Of Conservative Review Stance

FDA's "not approvable" action on Merck's Vioxx follow-on Arcoxia for the treatment of symptoms of osteoarthritis could be indicative of a conservative regulatory climate at the agency





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts